Reply to Focosi et al

Clin Infect Dis. 2023 Feb 8;76(3):554-555. doi: 10.1093/cid/ciac744.

Authors

Hana Golding¹, Surender Khurana¹

Affiliation

¹ Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, Maryland, 20993, USA.

PMID: 36074895
DOI: 10.1093/cid/ciac744

No abstract available

Publication types

Letter
Comment